Drug decision support provider Gold Standard/Elsevier, US, has announced that it will continue to publish transparent drug pricing information, including average wholesale price (AWP) and all other current and future pricing benchmarks. The announcement comes amidst statements by other drug database suppliers indicating they will discontinue publishing AWP in 2011.
Gold Standard/Elsevier supports transparent price benchmarks for payers (health plans, patients, government agencies and employers), pharmacies and other providers for prescription drugs. The company publishes reported and calculated drug prices that are clearly distinguished within the database, and adheres to strict internal policies for populating reported versus calculated pricing fields. Drug company reported prices of AWP, WAC (wholesale acquisition cost), CMS FUL (Federal Upper Limit), and Direct Price are included in Gold Standard’s database.
Gold Standard/Elsevier provides comprehensive drug pricing data via its Alchemy integrated drug database and ProspectoRx web-based drug pricing and analysis tool. Both sources offer the most frequent and accurate updates in the industry. Following review and confirmation by editorial professionals, price changes are published ‘live’ throughout the day as they are reported by drug companies. The company’s unique Price Change Indicator tracks pricing change catalysts consistently, reporting on whether the source came from the drug company’s reports, billing unit changes or errors.
Search for more decision support tools
